In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...

Study suggests a path forward for device therapy, though caveats are plenty ...

Using anticoagulation alone—and avoiding aspirin— appears to limit adverse events after left atrial appendage occlusion (LAAO) with the Watchman FLX device (Boston Scientific), an analysis of ...

New data presented at the Cardiovascular Research Technologies (CRT) 2023 meeting reinforced the safety and effectiveness of Boston Scientific Corp.’s Watchman FLX left atrial appendage occlusion ...

Boston Scientific (BSX) stock tumbled 9% to two-year lows after Watchman trial data revealed stroke concerns and Raymond James downgraded the stock.

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

The biggest names in cardiology tech gathered in New Orleans for the American College of Cardiology (ACC) Scientific Sessions ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Atrial fibrillation (AF) is an increasingly common heart rhythm disorder that affects approximately 59 million people worldwide 1 and increases stroke risk by five times compared to people with a ...